Moving toward combination lipid-lowering therapy for all patients with atherosclerotic cardiovascular disease-Reference-Cited by-同舟云学术

Moving toward combination lipid-lowering therapy for all patients with atherosclerotic cardiovascular disease

Published:2023-06 Issue: Volume:14 Page:100491
ISSN:2666-6677
Container-title:American Journal of Preventive Cardiology
language:en
Short-container-title:American Journal of Preventive Cardiology

Author:

Faridi Kamil F.^ORCID,Desai Nihar R.

Publisher

Elsevier BV

Subject

General Medicine

Reference16 articles.

1. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European atherosclerosis society consensus panel;Ference;Eur Heart J,2017

2. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American college of cardiology/American heart association task force on clinical practice guidelines;Grundy;Circulation,2019

3. Low-density lipoprotein cholesterol treatment rates in high risk patients: more disappointment despite ever more refined evidence-based guidelines;Toth;Am J Prev Cardiol,2021

4. Use of lipid-lowering therapies over 2 years in GOULD, a registry of patients with atherosclerotic cardiovascular disease in the US;Cannon;JAMA Cardiol,2021

5. Reasons for nonadherence to statins - a systematic review of reviews;Ingersgaard;Patient Prefer Adherence,2020

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Closing the Gaps in Care of Dyslipidemia: Revolutionizing Management with Digital Health and Innovative Care Models;Reviews in Cardiovascular Medicine;2023-12-13